ARS-583 inhibits downstream MAPK/PI3K signaling across the group of cell lines and directly inhibits the treatment of patients with the KRAS G12C mutation, which comprises 20% of lung cancers [55]. The gene discussed is KRAS; the disease is lung cancer.